P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)

Selpercatinib is a targeted, FDA-approved, oral, small-molecule inhibitor for the treatment of rearranged during transfection (RET) proto-oncogene mutation-positive cancer. Using genetically modified mouse models, we investigated the roles of the multidrug efflux transporters ABCB1 and ABCG2, the OA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yaogeng, Sparidans, Rolf W., Potters, Sander, Şentürk, Rahime, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617681/
https://www.ncbi.nlm.nih.gov/pubmed/34832869
http://dx.doi.org/10.3390/ph14111087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617681/
https://www.ncbi.nlm.nih.gov/pubmed/34832869
http://dx.doi.org/10.3390/ph14111087

Ejemplares similares